公开(公告)号：US20110190313A1

公开(公告)日：2011-08-04

申请号：US13058742

申请日：2009-08-11

申请人： Steve Pascoe ,  Deborah Quinn

发明人： Steve Pascoe ,  Deborah Quinn

IPC分类号： C07D401/14 ,  A61K31/496 ,  A61P9/12

CPC分类号： A61K31/506 ,  Y02A50/423

摘要： The present invention pertains to the use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof or a pyrimidylaminobenzamide of formula I wherein the radicals and symbols are as defined herein, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating pulmonary arterial hypertension (PAH), especially in patients who failed prior PAH therapy.

摘要翻译： 本发明涉及4-（4-甲基哌嗪-1-基甲基）-N- [4-甲基-3-（4-吡啶-3-基）嘧啶-2-基氨基）苯基] - 苯甲酰胺或 其药学上可接受的盐或式I的嘧啶基氨基苯甲酰胺，其中基团和符号如本文所定义，或其药学上可接受的盐，用于制备用于治疗肺动脉高压（PAH）的药物，特别是在以前的PAH治疗失败的患者中 。

公开(公告)号：US20090136965A1

公开(公告)日：2009-05-28

申请号：US11914152

申请日：2006-05-08

申请人： Peter Lloyd ,  Phil Lowe ,  Steve Pascoe

发明人： Peter Lloyd ,  Phil Lowe ,  Steve Pascoe

IPC分类号： G01N33/53

CPC分类号： G01N33/6854 ,  G01N33/536

摘要： We have found that when an antibody binds to (captures) its specific ligand, the antibody-ligand complex is redirected to a route of elimination which is different from that which occurs naturally for the specific ligand that is not bound to an antibody. As a consequence, the amount of antibody-bound ligand in the blood increases over time. The increase in total ligand concentration is a property that is specific to the patient to whom the antibody is administered. Accordingly, the invention provides a method for diagnosing disease in a subject and a method for identifying the most appropriate treatment for a particular patient. Patients who produce more ligand, and thus more antibody-ligand complex, may be more likely to have a disease which is predominantly driven by that ligand. These patients should respond better to a therapy targeted against that ligand. The better understanding of the underlying malfunctions in disease biology provided by the methods of the invention, in respect of the rates of production of natural ligands in health and disease, provides a logical and targeted selection of the appropriate treatments to address specific biological abnormalities.

摘要翻译： 我们已经发现，当抗体结合（捕获）其特异性配体时，抗体 - 配体复合物被重定向到消除途径，其不同于不与抗体结合的特异性配体天然存在的途径。 因此，血液中抗体结合配体的量随时间增加。 总配体浓度的增加是对施用抗体的患者特异性的特性。 因此，本发明提供了用于诊断受试者疾病的方法以及用于鉴定特定患者最合适治疗的方法。 产生更多配体，因此更多的抗体 - 配体复合物的患者可能更可能具有主要由该配体驱动的疾病。 这些患者应该对针对该配体的治疗效果更好。 通过本发明方法提供的关于疾病生物学中潜在的功能障碍的更好的理解，就天然配体在健康和疾病中的生产率而言，提供了适当的治疗方案的合乎逻辑和有针对性的选择，以解决具体的生物学异常。